Australia markets closed

OncoZenge AB (publ) (8LY.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.3155+0.0035 (+1.12%)
At close: 08:20AM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
0
0
0
0
0
Cost of revenue
-
-
0
0
0
Gross profit
-
-
0
0
0
Operating expenses
Research development
-
-
37,639
216
0
Selling general and administrative
-
-
5,928
4,677
801
Total operating expenses
15,902
15,902
20,401
4,894
801
Operating income or loss
-15,902
-15,902
-20,401
-4,894
-801
Interest expense
-
-
0
0
0
Income before tax
-15,902
-15,902
-43,569
-4,894
-801
Income tax expense
0
0
3,077
-1,008
-165
Income from continuing operations
-15,902
-15,902
-46,646
-3,886
-636
Net income
-15,902
-15,902
-46,646
-3,886
-636
Net income available to common shareholders
-15,902
-15,902
-46,646
-3,886
-636
Basic EPS
-1.48
-1.36
-3.98
-0.33
-0.09
Diluted EPS
-1.48
-1.36
-3.98
-0.33
-0.09
Basic average shares
11,713
11,713
11,713
11,713
7,275
Diluted average shares
11,713
11,713
11,713
11,713
7,275